Neprilysin in Heart Failure-Reference-Cited by-同舟云学术

Neprilysin in Heart Failure

Published:2015-08 Issue:8 Volume:3 Page:637-640
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Bayés-Genís Antoni

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference6 articles.

1. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE);Packer;Circulation,2002

2. Angiotensin-neprilysin inhibition versus enalapril in heart failure;McMurray;N Engl J Med,2014

3. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure;Vodovar;J Am Coll Cardiol HF,2015

4. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure;Packer;Circulation,2015

5. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients;Bayes-Genis;J Am Coll Cardiol,2015

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure;International Journal of Molecular Sciences;2022-09-26

2. Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure;Critical Reviews in Clinical Laboratory Sciences;2021-07-01

3. Where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials;Heart Failure Reviews;2021-05-29

4. Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study;BMC Cardiovascular Disorders;2020-08-06

5. Novel pharmacotherapies for heart failure;Emerging Technologies for Heart Diseases;2020